Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 11 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-10.88 Insider Own37.27% Shs Outstand9.19M Perf Week-2.23%
Market Cap20.39M Forward P/E- EPS next Y-2.65 Insider Trans-0.01% Shs Float7.31M Perf Month-6.91%
Income-57.28M PEG- EPS next Q-1.02 Inst Own43.72% Short Float0.53% Perf Quarter-53.21%
Sales3.37M P/S6.05 EPS this Y80.36% Inst Trans-12.74% Short Ratio0.28 Perf Half Y-31.64%
Book/sh4.64 P/B0.38 EPS next Y-53.18% ROA-61.46% Short Interest0.04M Perf Year-80.58%
Cash/sh4.10 P/C0.43 EPS next 5Y- ROE-91.46% 52W Range1.55 - 10.64 Perf YTD-54.55%
Dividend Est.- P/FCF- EPS past 5Y21.95% ROI-103.87% 52W High-83.55% Beta1.06
Dividend TTM- Quick Ratio2.45 Sales past 5Y57.51% Gross Margin-57.08% 52W Low12.90% ATR (14)0.12
Dividend Ex-Date- Current Ratio2.45 EPS Y/Y TTM21.33% Oper. Margin-1636.34% RSI (14)40.13 Volatility5.15% 6.30%
Employees6 Debt/Eq0.40 Sales Y/Y TTM185.68% Profit Margin-1699.26% Recom3.00 Target Price12.50
Option/ShortNo / Yes LT Debt/Eq0.29 EPS Q/Q51.83% Payout- Rel Volume0.39 Prev Close1.82
Sales Surprise1.31% EPS Surprise-83.22% Sales Q/Q2512.26% EarningsMar 19 BMO Avg Volume135.98K Price1.75
SMA20-2.37% SMA50-15.73% SMA200-55.95% Trades Volume52,720 Change-3.85%
Date Action Analyst Rating Change Price Target Change
Nov-24-21Upgrade Oppenheimer Perform → Outperform $7
Aug-21-19Downgrade Oppenheimer Outperform → Perform
Apr-30-19Initiated Jefferies Buy $18
Dec-13-18Initiated Chardan Capital Markets Buy $20
Mar-19-18Initiated H.C. Wainwright Buy $20
Jan-29-18Initiated Piper Jaffray Overweight $16
Mar-19-24 08:10AM
Feb-20-24 12:15PM
Feb-09-24 09:41AM
05:47AM Loading…
Feb-08-24 04:15PM
Feb-02-24 12:00PM
Jan-16-24 08:47AM
Jan-04-24 07:00AM
Dec-27-23 07:00AM
Dec-07-23 07:00AM
Nov-14-23 08:55AM
Nov-09-23 07:19AM
07:00AM Loading…
Nov-07-23 07:00AM
Nov-02-23 10:00AM
Oct-03-23 04:15PM
Sep-29-23 07:00AM
Sep-28-23 11:15AM
Sep-27-23 12:30PM
Sep-21-23 07:00AM
Sep-19-23 11:00AM
Aug-10-23 08:40AM
Jul-11-23 07:00AM
Jun-28-23 07:00AM
Jun-27-23 07:00AM
Jun-08-23 06:45AM
06:45AM Loading…
Jun-05-23 06:45AM
May-24-23 06:35AM
May-23-23 06:50AM
May-13-23 08:21AM
May-11-23 12:38PM
May-09-23 07:15AM
May-04-23 10:00AM
Apr-28-23 05:12PM
Mar-29-23 07:55AM
Mar-28-23 06:52AM
Mar-20-23 06:55AM
Mar-10-23 08:35AM
Mar-08-23 07:00AM
Mar-07-23 08:35AM
Jan-24-23 06:57AM
Jan-19-23 06:58AM
Jan-17-23 10:00AM
Jan-16-23 12:00PM
Jan-14-23 07:17AM
Jan-05-23 06:58AM
Jan-03-23 06:58AM
Dec-15-22 10:49AM
Dec-04-22 09:27AM
Nov-30-22 04:15PM
Nov-10-22 08:05AM
Oct-18-22 11:15AM
Sep-06-22 07:00AM
Aug-23-22 07:00AM
Aug-11-22 03:50PM
Jul-28-22 07:00AM
Jul-12-22 07:00AM
Jun-29-22 07:00AM
Jun-28-22 07:00AM
Jun-27-22 10:06AM
Jun-21-22 07:00AM
Jun-01-22 07:00AM
May-24-22 07:00AM
May-12-22 10:51AM
May-05-22 07:00AM
Apr-28-22 07:00AM
Apr-26-22 07:00AM
Apr-01-22 07:00AM
Mar-17-22 08:25AM
Mar-10-22 07:00AM
Mar-03-22 07:00AM
Feb-24-22 07:00AM
Feb-08-22 07:00AM
Jan-11-22 08:59AM
Jan-06-22 07:00AM
Dec-24-21 12:00PM
Nov-30-21 10:54AM
Nov-22-21 07:45PM
Nov-18-21 01:04PM
Nov-17-21 10:45AM
Nov-12-21 11:29AM
Synlogic, Inc. is a biopharmaceutical company which engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on December 20, 2007 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Awad AntoineChief Operating OfficerApr 02 '24Sale1.7337264433,859Apr 04 04:00 PM
Dooley Mary BethHead of FinanceApr 02 '24Sale1.7318832515,231Apr 04 04:00 PM